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 CURRENTOPINION What will surgical coronary revascularization
look like in 25 years?
Etem Caliskana,b, Maximilian Y. Emmerta,b, and Volkmar Falka,b,c,d
Purpose of review
Coronary artery bypass grafting evolved in incremental but significant steps since its introduction. Here, we
provide an update on operative techniques, choice of conduits, patient selection/decision-making and
primary and secondary prevention measures with potential of influencing the future of coronary artery
bypass grafting (CABG) surgery.
Recent findings
Associated mortality of off-pump CABG (OPCAB) procedures performed in high-volume OPCAB centers
(164 cases per year) and by experienced surgeons (48 cases per year) was reduced compared with
on-pump CABG with two or more grafts suggesting a volume-based dependency of outcomes in CABG
procedures with high-technical complexity. Ten-year results from the recent Arterial Revascularization Trial
showed no significant between-group difference for the primary and secondary outcome. Total arterial
revascularization using composite bilateral internal mammary artery-Y-conduits through a limited access
mini-thoracotomy was not only shown to be feasible but a safe and reproducible procedure with excellent
midterm outcomes. The most recent Randomized Trial of Endoscopic or Open Vein-Graft Harvesting for
Coronary-Artery Bypass (REGROUP) trial demonstrated no significant difference between open vein-graft
harvesting and endoscopic vein-graft harvesting in the occurrence of major adverse cardiac events.
Summary
Adherence to the most recent guidelines on myocardial revascularization is a key component for providing
state-of the CABG surgery. Trends to lesser invasiveness in surgical coronary revascularization will gain
momentum and is expected – with further improvements – to be the mainstay of future surgical coronary
revascularization strategies.
Keywords
coronary artery bypass grafting, coronary artery disease, coronary computed tomography angiography,
minimally invasive direct coronary artery bypass grafting, multiarterial grafting, off-pump coronary artery
bypass, totally endoscopic coronary bypass grafting
INTRODUCTION
Today, coronary artery disease (CAD) is the most
common cause of mortality and morbidity in
developed countries [1]. In the subsequent years
and decades after Sabiston performed the first,
nonmechanical, sutured anastomosis of a saphe-
nous vein graft to the right coronary artery to
be the first coronary artery bypass grafting
(CABG) procedure and remains today the standard
surgical revascularization treatment in patients
with complex multivessel CAD and/or left main
disease, diabetes, or reduced left ventricular func-
tion [2–6]. Substantial efforts have been invested in
operative techniques, choice of conduits, patient
selection/decision-making and primary and sec-
ondary prevention to address the invasiveness
and the safety of CABG procedures while
improving short-term and long-term outcomes
throughout the past decades [7].
The current review aims to provide an overview
of recent developments with the potential of
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influencing the fate of surgical coronary revascular-
ization in the upcoming decades.
MARKET SHARE OUTLOOK
Despite technological advancements of percutane-
ous coronary intervention (PCI) in the recent years,
today with approximately 371000 procedures per
year in the United States and 40–60 procedures per
100000 inhabitants in Europe, the utilization of
CABGworldwide is againon the rise as a consequence
of large-scale trials demonstrating the survival
benefits associated with CABG [8–10]. Although
the incidence has decreased over the past decade,
CAD remains the leading cause of mortality world-
wide [1]. However, a further increase due to stress,
unhealthy diets, obesity reaching epidemic propor-
tions, and sedentary lifestyle together with the aging
population is likely in the coming decades. Accord-
ingly, a further growth of the global CABG market is
highly expected for the upcoming decades.
GUIDELINE ADHERENCE AND IMPACT OF
PUBLIC REPORTING
Clinical practice guidelines summarizing and
evaluating all available evidence aim to assist
physicians in selecting the best management strat-
egies for an individual patient thus improving
the quality of outcomes. As such, adherence to
the most recent 2018 ESC/EACTS Guidelines on
myocardial revascularization is a key component
for providing state-of-the-art CABG surgery. Public
performance reporting (PPR) and patient-reported
outcomes as a means of performance measure
aim to further improve the quality of care and
informed patient choice and is being increasingly
endorsed in modern CABG surgery practice in the
United States and Europe [11]. A recent systematic
review and meta-analysis of the impact of PPR
on market share, mortality, and patient mix out-
comes associated with CABG demonstrated
some evidence that PPR reduces mortality rates
in CABG [12
&&
]. An analysis of risk-adjusted CABG
outcomes of 39 400 patients in Massachusetts
from 2003 to 2014, a mandatory public reporting
state, revealed superior results compared with the
Society of Thoracic Surgeons National Database
data [13]. In light of controversial unintended con-
sequences of public reporting such as risk aversion
and denial of care to high-risk patients, further
efforts need to be invested in implementing PPR
systems throughout the world – either voluntarily
or mandatory.
OPERATIVE TECHNIQUES
The CABG procedure is traditionally carried out by
use of cardiopulmonary bypass (CPB) (on-pump
CABG) and is currently the most preferred tech-
nique in the Western world rather than in develop-
ing countries in Asia due to high procedural cost
associated with cardiopulmonary bypass (CPB)
[14,15]. The concept of CABG without the utiliza-
tion of CPB (off-pump coronary artery bypass;
OPCAB) to circumvent deleterious effects associated
with CPB have been reported as early as in the 1970s
by Trapp and Ankeney with favorable outcomes
[16,17]. As such, avoiding aortic cross clamping in
particular by anaortic techniques (e.g., in-situ or
composite Y-/T-grafting) without manipulation of
the ascending aorta or by minimal manipulation
using the Heartstring system (Maquet Cardiovascu-
lar, San Jose, California) contributed largely to the
reduced incidence of stroke after OPCAB in patients
with high risk of stroke [18,19]. Although OPCAB
procedures were performed with high enthusiasm
in the subsequent years, the strong body of evidence
derived from large randomized clinical trials
(RCTs) has only been provided in this decade. How-
ever, in the hand of inexperienced surgeons, OPCAB
is associated with inferior early and late graft
patency rates, possibly compromising long-term
survival. Gaudino et al. [20] demonstrated surgeons’
inexperience with the OPCAB procedure to be asso-
ciated with increased mortality. In-line with this
finding, Benedetto et al. [21
&&
] further highlighted
KEY POINTS
 CABG remains the standard surgical revascularization
treatment in patients with complex multivessel CAD
and/or left main disease, diabetes, or reduced left
ventricular function.
 CABG surgery with intense structured training in highly
dedicated programs needs to be implemented as a
subspecialty within cardiac surgery.
 New technological developments in robotic CABG
surgery may provide broader applicability in selected
patient populations.
 While further evidence on the merits of multiarterial
grafting is necessary, significant efforts are being
invested to optimize patency outcomes of saphenous
vein grafts.
 New diagnostic tools such as coronary computed
tomography angiography, FFR instantaneous wave-free
ratio and fusion imaging techniques involving
anatomical and functional modalities may in future
impact the patient selection and decision making for a
patient-tailored approach.
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a volume-based dependency of outcomes in OPCAB
surgery in a retrospective analysis of the Nationwide
Inpatient Sample database including a total of
2094 094 patients undergoing on-pump and off-
pump coronary artery bypass surgery.
Associated mortality of OPCAB procedures per-
formed in high-volume off-pump CABG centers
(164 cases per year) and by experienced surgeons
(48 cases per year) was reduced compared with on-
pump coronary artery bypass grafting with two or
more grafts [21
&&
]. Not only these observations stim-
ulated Mack and Taggart to propose CABG surgery
to be a subspecialty within cardiac surgery [22
&&
].
Not surprisingly, Watkins et al. [23
&&
] observed an
improvement of survival after implementation of a
dedicated subspecialized CABG program in a retro-
spective, single-center analysis. In light of recent
developments in cardiac surgery with multidisci-
plinary heart teams of specialists and specific exper-
tise dedicated to heart failure therapies (transplant,
mechanical circulatory support), mitral valve thera-
pies, aortic valve therapies and thoracic aortic ther-
apies, this proposal seems highly justified and may
shape the upcoming future of surgical coronary
revascularization.
MINIMALLY INVASIVE APPROACHES
Themomentum gained by catheter-based aortic and
mitral valve therapies driven by the desire of
patients for lesser invasiveness and faster recovery
is undeniable. This trend cannot and is not ignored
for CABG surgery and is expected – with further
improvements – to be the mainstay of future surgi-
cal coronary revascularization strategies. As such, in
an effort to mitigate the invasiveness of CABG by
avoiding open sternotomy, minimally invasive
direct CABG (MIDCAB) with grafting of the left
internal mammary artery (LIMA) to the left anterior
descending (LAD) in off-pump technique through a
limited-access minithoracotomy emerged in the
1990s as a promising alternative. However, this
access is not limited to single anastomosis and total
arterial revascularization using composite bilateral
internal mammary artery (BIMA)-Y-conduits was
not only shown to be feasible but a safe and repro-
ducible procedure with excellent midterm out-
comes [24,25
&&
]. The Minimally Invasive coronary
surgery compared with STernotomy coronary artery
bypass grafting (MIST) trial, a multicentre, prospec-
tive, open label, randomized control trial aims to
compare quality of life and recovery in the early
postoperative period, between patients with multi-
vessel CAD undergoing CABG by minimally inva-
sive approach versus sternotomy. The trial has
started in 2018 with an anticipated randomization
of 88 patients for each group and is currently enroll-
ing [26].
Another approach emerged by integrating PCI
for non-LAD territories with simultaneous or
sequential MIDCAB as hybrid coronary revasculari-
zation (HCR). Further refinements include video-
assisted or robotic-assisted harvesting of the LIMA
graft. Despite encouraging results mainly published
from retrospective single-center studies with short-
term follow-up (FU) and rather small sample sizes,
evidence for HCR remains limited and hypothesis
generating [27–29]. In one of the few RCTs, the 5-
year clinical follow-up of the HYBRID (Hybrid
Revascularization for Multivessel Coronary Artery
Disease) trial with a total of 200 patients randomly
assigned to undergo HCR or conventional CABG
showed similar 5-year all-cause mortality when
compared with conventional CABG [30]. The
Hybrid Coronary Revascularization Trial (Clinical-
Trials.gov Identifier: NCT03089398), a prospective,
multicenter randomized comparative effectiveness
trial of HCR compared with multivessel PCI with
drug-eluting stents in patients with multivessel
CAD involving the LAD or left main territories with
an anticipated enrollment of 2354 patients was
expected to provide robust evidence from a large-
scale RCT in support for HCR. However, due to slow
enrollment, this trial was stopped early after only
200 patients were randomized.
A further evolution of minimally invasive tech-
niques involves robot-assisted totally endoscopic
grafting of the LIMA–LAD anastomosis as part
of HCR as well as multiple bypass grafting in
totally endoscopic coronary bypass grafting
(TECAB) with the aid of highly sophisticated tele-
manipulation systems. Several groups reported on
the safety and feasibility of TECAB procedures with
outcomes comparable with open CABG procedures
[31,32,33
&
,34]. However, achievement of high-
level-specific skills is mandatory and requires
intense training in robotic techniques. Despite
incremental improvements in robotic techniques
and equipment, devices facilitating anastomosis
(distal anastomotic-connectors/coupling devices)
thus alleviating the complexity of the procedure
still needs further attention. Midterm results of the
Multicenter Assessment of Grafts in Coronaries
(MAGIC) study demonstrated the commercially
available C-Port distal anastomotic device to be
safe and effective in creating the distal anastomosis
with equivalent patency rates and a statistically
significant reduction in midterm graft occlusion
to hand-sewn grafts at 12months [35
&&
].Meanwhile
adoption of this technique remains in dedicated
centers, restricted to very few highly specialized
surgeons.
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However, a new Excimer laser-assisted nonoc-
clusive anastomosis-based coronary connector,
facilitating sutureless bypass grafting has been
recently developed and is currently in preclinical
investigation with promising short-term results
[36]. Clinical introduction in a pilot study is
expected upon completion of long-term safety eval-
uations in porcine models. The technique has been
previously implemented in neurosurgical intracra-
nial-to-intracranial or intracranial-to-extracranial
bypasses with promising safety and efficacy results
[37]. As to whether a translation into cardiac surgery
is feasible remains to be seen. Certainly, any new
technology capable of facilitating a safe and durable
anastomosis may be the game changer in robotic
CABG surgery in the upcoming decades.
Figure 1 illustrates applicability in comparison
with complexity of various CABG techniques.
CHOICE OF CONDUIT
While grafting of LIMA to LAD is currently an
established approach in CABG surgery due to its
proven excellent patency rates with improved sur-
vival and freedom from adverse cardiac events, the
conduit of choice for non-LAD lesions remains the
matter of a heated debate in the cardiovascular
community [38]. Traditionally, utilization of the
saphenous vein graft (SVG) is common in CABG
surgery but due to vein graft disease/failure (VGD/F)
with graft-occlusion rates of 40–50% after 10 years,
its application has been challenged in the last
decades. As such, utilization of the right internal
mammary artery, the radial artery (RA) and the right
gastroepiploic artery has been under intensive inves-
tigations [39–42]. Despite accumulating evidence
for BIMA grafting from large nonrandomized risk-
adjusted registry data and meta-analyses and
unequivocal recommendations in recent US and
European guidelines on myocardial revasculariza-
tion, today adoption of BIMA grafting in clinical
routine remains fairly low due to added technical
complexity of the CABG procedure, perceived
increased morbidity due to associated deep sternal
wound infections and doubts on the long-term
survival benefits [2,3,41,43–46]. To address these
issues, the large-scale prospective randomized mul-
ticenter Arterial Revascularization Trial was initiated
more than a decade ago and 10-year results have
recently been published [47
&&
]. A total of 3102
patients scheduled for CABG were randomly
assigned to undergo single (n¼1545) or bilateral
(n¼1548) IMA grafting from June 2004 to Decem-
ber 2007. The primary outcomewas defined as death
from any cause at 10 years and the secondary out-
come as a composite of death from any cause,
myocardial infarction (MI), or stroke. A significant
between-group difference for the primary and sec-
ondary outcome was not observed in the intention-
to-treat analysis. The results of this trial with ade-
quate long-term FU may be disappointing for advo-
cates of multiarterial grafting in CABG surgery while
opponentsmay feel vindicated in their reluctance to
adopt multiarterial techniques. However, the results
of the intention-to-treat-analysis need to be inter-
preted with caution since a high crossover between
groups occurred in the trial. 14% of the patients
from the bilateral-graft group eventually received
single IMA grafting, and 22% of the patients ran-
domly assigned to the single IMA group received an
additional RA graft resulting in multiarterial graft-
ing which is known to result in improved patency
and fewer clinical events. The nonrandomized as-
treated analysis comparing patients with one
single arterial graft and patients with multiarterial
grafts however indicated a difference in favor of
multiple arterial grafting. The Randomized compar-
ison of the Outcome of Single versus Multiple Arte-
rial grafts (ROMA; ClinicalTrials.gov Identifier:
NCT03217006) trial with an anticipated enrolment
of 4300 patients started recruitment last year and
may provide with amore strict methodology further
insight on multiarterial grafting and impact future
grafting approaches.
As for another arterial graft, the radial artery has
been shown to offer superior patency rates compared
with SVGs, yet a recent patient-level combined anal-
ysis of randomized, controlled trials performed by
FIGURE 1. Applicability in comparison with complexity of
various coronary artery bypass grafting techniques. The size
of the circle is proportional to the number of articles
published for each technique up to June 2018. AnCABG,
anaortic coronary artery bypass surgery; CABG, coronary
artery bypass surgery; HCR, hybrid coronary
revascularization; MICS, minimally invasive coronary
surgery; MAG, multiarterial grafting. Reproduced from
Gaudino M, Bakaeen F, Davierwala P, et al. New strategies
for surgical myocardial revascularization. Circulation
2018;138(19):2160–8.
Coronary artery surgery
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The Radial Artery Database International Alliance
investigators failed to demonstrate a significant sur-
vival benefit despite superior patency of the RA graft
compared with SVGs [48
&
,49].
Meanwhile, significant efforts have been
invested in addressing the high failure rates of SVGs.
The concepts of applying venous external stents, no-
touch SVG harvesting techniques and storage of
veins after harvesting in dedicated preservation
solutions together with high adoption rates of
optimized medical therapy post-CABG may further
reduce the occurrence of VGD/F and impact
the future of conduit choice in CABG surgery
[50
&&
,51–53]. The most recent Randomized Trial
of Endoscopic or Open Vein-Graft Harvesting for
Coronary-Artery Bypass (REGROUP) trial demon-
strated no significant difference between open
vein-graft harvesting and endoscopic vein-graft har-
vesting in the occurrence of major adverse cardiac
events [54
&&
]. With the drive for lesser invasiveness,
a wider adoption in future clinical practice is
expected and inevitable.
NEW DIAGNOSTIC TOOLS AND GUIDANCE
IN CORONARY ARTERY BYPASS
GRAFTING SURGERY
Noninvasive coronary computed tomography angi-
ography (CCTA) performed on modern high-resolu-
tion, multidetector scanners with high sensitivity
(95–99%) and increasing specificity (64–83%) may
represent an interesting alternative to and challenge
standard invasive coronary angiography in the diag-
nosis of CAD. Results of the SYNTAX III REVOLU-
TION trial demonstrated that in patients with left
main or three-vessel disease a heart team treatment
decision-making based onCCTA showed high agree-
ment with the decision derived from conventional
coronary angiography indicating noninferiority of
CCTA compared with invasive angiography [55
&&
].
While fraction flow reserve (FFR)-guided percu-
taneous revascularization strategies have shown to
improve long-termoutcomes, equivalent data on the
impact of FFR guidance in CABG surgery remains
limited [56,57]. In a retrospective analysis of 627
consecutive patients undergoing either angiogra-
phy-guided or FFR-guided CABG, the rate of overall
death orMIwas significantly lower in the FFR-guided
as compared with the angiography-guided group at
up to 6 years of FU [58]. In contrast, a small RCT by
Thuesen et al. [59] showed similar graft failure rates
and clinical outcomes at 6-month FU in 100 patients
for FFR-guided andangiography-guidedCABG. Inter-
estingly, FFR in deferred lesions was significantly
reduced after 6 months and treated subsequently
with PCI if the value dropped to less than 0.80 in
symptomatic patients. High-quality large-scale RCTs
are warranted to evaluate the impact of invasive
functionally guided surgical revascularization. As
such, the ongoing Graft Patency After FFR-guided
versus angiography-guided CABG (GRAFFITI) trial,
first of its kind, will provide significant data to
optimized graft site selection in surgical revasculari-
zation [60
&&
]. Further cardiac imaging technologies
in practice and development such as fusion imaging
involving anatomical and functional modalities
by incorporating CCTA, single photon computed
tomography cardiac MRI, and three-dimensional
speckle tracking/strain stress echocardiography will
significantly improve diagnostic accuracy and guide
decisionmaking in futureCABGpatients (Fig. 2) [61].
PRIMARY AND SECONDARY
PREVENTION, PREHABILITATION
The latest 5-year results from the open-label, multi-
center, parallel-group SCOT-HEART trial demon-
strated that the use of CTA in addition to standard
care in patients with stable chest pain resulted in a
significantly lower rate of death from coronary heart
disease or nonfatal MI at 5 years than standard care
alone [62
&
]. The investigators attributed this observa-
tion to changes of planned investigations and treat-
ments along with increased adherence to primary
prevention medications during the FU period. Not
only primary, but also secondary prevention mea-
sures play a crucial role in themanagement of CABG
patients by improved survival [63].
As such, suboptimal medical management in
CABG as shown in many randomized trials needs
further optimization by means of adopting recent
guidelines recommendations [63,64]. To further
improve outcomes in CABG, recent trends of pre-
operative conditioning by means of improving the
functional capacity through multimodal prehabili-
tation (preoperative rehabilitation) programs need
further attention [65].
CONCLUSION
CABG surgery evolved in incremental but signifi-
cant steps since its introduction. The fate of surgical
coronary revascularization in 25 years will mainly
be determined by the adequate incorporation of
present techniques, choice of grafts and patient
selection and decision making based on individual
patient risks as well as wider adoption of available
minimally invasive techniques. Subspecializing
CABG within cardiac surgery by any means of tech-
nique seems inevitable and requires intense struc-
tured training in highly dedicated programs. The
search for the second best conduit remains in
Surgical coronary revascularization in 25 years Caliskan et al.
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FIGURE 2. Cardiac hybrid imaging combining three-dimensional echocardiography and coronary computed tomography
angiography allows assessing comprehensive anatomic and functional information at the same time. Chronic total occlusion of
the right coronary artery (panel a, arrow) and a calcified intermediate stenosis of the left anterior descending artery (panel a,
arrowhead). Wall motion abnormality in the inferior segments as well as a small area in the apical region depicted by polar
mode in three-dimensional-strain imaging (panel b, grey-scaled arrow). Anatomical matching between the three-dimensional
strain dataset and the main coronary arteries from three-dimensional coronary computed tomography angiography dataset
based on size and orientation from coronary computed tomography angiography (panels c and d). The coronary tree with
superimposed three-dimensional strain dataset (panel e and f) indicating that the large ischemic region (grey-scaled
arrowhead) is subtended by the right coronary artery (arrow), while the small, prognostically nonrelevant ischemic region is
subtended by the left anterior descending. Reproduced from [61].
Coronary artery surgery
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progress and will highly affect outcomes in patients
with CAD progressively presenting in younger
patients. Available and upcoming diagnostic tools
such as CCTA, FFR or instantaneous wave-free ratio
need further attention and may contribute signifi-
cantly in the patient selection and decision making
process. Efforts of reducing the invasiveness of the
procedure should remain in the focus but without a
breakthrough of technologies robotic coronary sur-
gery will be forced to carve a niche existence in the
hands of highly specialized centers and surgeons.
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